GILEAD SCIENCES, INC. Business Acquisition, Pro Forma Revenue
GILEAD SCIENCES, INC. (GILD) reported Business Acquisition, Pro Forma Revenue of $26.13 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2018-02-27
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2012-12-31 was $2.59B, a 17.63% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2012-09-30 was $2.43B, a 14.37% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2012-06-30 was $2.41B, a 12.54% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2012-03-31 was $2.28B, a 18.50% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for fiscal 2017 was $26.13B, a 14.03% decline from fiscal 2016.
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for fiscal 2016 was $30.39B.
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for fiscal 2012 was $9.70B, a 15.71% increase from fiscal 2011.
- GILEAD SCIENCES, INC. business acquisition, pro forma revenue for fiscal 2011 was $8.39B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | $26.13B 10-K · filed 2018-02-27 | |||
| 2016-12-31 | $30.39B 10-K · filed 2018-02-27 | |||
| 2012-12-31 | $2.59B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $5.01B derived: sum of 2 quarters · filed 2013-02-27 | $7.42B derived: sum of 3 quarters · filed 2013-02-27 | $9.70B 10-K · filed 2013-02-27 |
| 2012-09-30 | $2.43B 10-Q · filed 2012-11-06 | $4.83B derived: sum of 2 quarters · filed 2012-11-06 | $7.11B 10-Q · filed 2012-11-06 | $9.31B derived: sum of 4 quarters · filed 2013-02-27 |
| 2012-06-30 | $2.41B 10-Q · filed 2012-08-01 | $4.69B 10-Q · filed 2012-08-01 | $6.89B derived: sum of 3 quarters · filed 2013-02-27 | $9.01B derived: sum of 4 quarters · filed 2013-02-27 |
| 2012-03-31 | $2.28B 10-Q · filed 2012-05-04 | $4.48B derived: sum of 2 quarters · filed 2013-02-27 | $6.60B derived: sum of 3 quarters · filed 2013-02-27 | $8.74B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-12-31 | $2.20B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $4.32B derived: sum of 2 quarters · filed 2013-02-27 | $6.46B derived: sum of 3 quarters · filed 2013-02-27 | $8.39B 10-K · filed 2013-02-27 |
| 2011-09-30 | $2.12B 10-Q · filed 2012-11-06 | $4.26B derived: sum of 2 quarters · filed 2012-11-06 | $6.19B 10-Q · filed 2012-11-06 | |
| 2011-06-30 | $2.14B 10-Q · filed 2012-08-01 | $4.06B 10-Q · filed 2012-08-01 | ||
| 2011-03-31 | $1.93B 10-Q · filed 2012-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |